Latest Breaking News On - The phase 1 2 her ram study nct04888663 - Page 1 : comparemela.com

Trastuzumab plus ramucirumab and paclitaxel yielded promising efficacy and a manageable safety profile among patients with previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.

South koreaRepublic of koreaTrastuzumab herceptinGastric cancerGastroesophageal junction adenocarcinomaTrastuzumab deruxtecanHer2 positive gastric or gastroesophageal junction gej cancerTrastuzumab containing regimenJournal of clinical oncologyThe phase 1 2 her ram study nct04888663